Monoamine Oxidase Inhibitors: A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)Monoamine Oxidase: An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4.Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.Nialamide: An MAO inhibitor that is used as an antidepressive agent.Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)Iproniazid: An irreversible inhibitor of monoamine oxidase types A and B that is used as an antidepressive agent. It has also been used as an antitubercular agent, but its use is limited by its toxicity.Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.Tyramine: An indirect sympathomimetic. Tyramine does not directly activate adrenergic receptors, but it can serve as a substrate for adrenergic uptake systems and monoamine oxidase so it prolongs the actions of adrenergic transmitters. It also provokes transmitter release from adrenergic terminals. Tyramine may be a neurotransmitter in some invertebrate nervous systems.Bufotenin: A hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics. Bufotenin has been used as a tool in CNS studies and misused as a psychedelic.Methoxydimethyltryptamines: Compounds that contain the biogenic monoamine tryptamine and are substituted with one methoxy group and two methyl groups. Members of this group include several potent serotonergic hallucinogens found in several unrelated plants, skins of certain toads, and in mammalian brains. They are possibly involved in the etiology of schizophrenia.NADPH Oxidase: A flavoprotein enzyme that catalyzes the univalent reduction of OXYGEN using NADPH as an electron donor to create SUPEROXIDE ANION. The enzyme is dependent on a variety of CYTOCHROMES. Defects in the production of superoxide ions by enzymes such as NADPH oxidase result in GRANULOMATOUS DISEASE, CHRONIC.Serotonin Syndrome: An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. It is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the CNS at the serotonin 1A receptor.Serotonin: A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.Antidepressive Agents: Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.Methyltyrosines: A group of compounds that are methyl derivatives of the amino acid TYROSINE.Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.Fenclonine: A selective and irreversible inhibitor of tryptophan hydroxylase, a rate-limiting enzyme in the biosynthesis of serotonin (5-HYDROXYTRYPTAMINE). Fenclonine acts pharmacologically to deplete endogenous levels of serotonin.Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.Nictitating Membrane: A fold of the mucous membrane of the CONJUNCTIVA in many animals. At rest, it is hidden in the medial canthus. It can extend to cover part or all of the cornea to help clean the CORNEA.5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.Vesicular Monoamine Transport Proteins: A family of vesicular amine transporter proteins that catalyze the transport and storage of CATECHOLAMINES and indolamines into SECRETORY VESICLES.PropylaminesTryptamines: Decarboxylated monoamine derivatives of TRYPTOPHAN.Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.AcetophenonesAmines: A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed)Xanthine Oxidase: An iron-molybdenum flavoprotein containing FLAVIN-ADENINE DINUCLEOTIDE that oxidizes hypoxanthine, some other purines and pterins, and aldehydes. Deficiency of the enzyme, an autosomal recessive trait, causes xanthinuria.Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.HydrazinesBiogenic Monoamines: Biogenic amines having only one amine moiety. Included in this group are all natural monoamines formed by the enzymatic decarboxylation of natural amino acids.Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.Onium Compounds: Ions with the suffix -onium, indicating cations with coordination number 4 of the type RxA+ which are analogous to QUATERNARY AMMONIUM COMPOUNDS (H4N+). Ions include phosphonium R4P+, oxonium R3O+, sulfonium R3S+, chloronium R2Cl+Sympathomimetics: Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.Imidazoline Receptors: Receptors of CLONIDINE and other IMIDAZOLINES. Activity of the ligands was earlier attributed to ADRENERGIC ALPHA-2 RECEPTORS. Endogenous ligands include AGMATINE, imidazoleacetic acid ribotide, and harman.Antidepressive Agents, Tricyclic: Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.Dopamine: One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.Norepinephrine: Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.Brain: The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.Vesicular Biogenic Amine Transport Proteins: Integral membrane proteins of the LIPID BILAYER of SECRETORY VESICLES that catalyze transport and storage of biogenic amine NEUROTRANSMITTERS such as ACETYLCHOLINE; SEROTONIN; MELATONIN; HISTAMINE; and CATECHOLAMINES. The transporters exchange vesicular protons for cytoplasmic neurotransmitters.Phenethylamines: A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed)Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.Superoxides: Highly reactive compounds produced when oxygen is reduced by a single electron. In biological systems, they may be generated during the normal catalytic function of a number of enzymes and during the oxidation of hemoglobin to METHEMOGLOBIN. In living organisms, SUPEROXIDE DISMUTASE protects the cell from the deleterious effects of superoxides.Serotonin Uptake Inhibitors: Compounds that specifically inhibit the reuptake of serotonin in the brain.Drug Interactions: The action of a drug that may affect the activity, metabolism, or toxicity of another drug.Brain Chemistry: Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states.Reactive Oxygen Species: Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of signal transduction and gene expression, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS.Tetrabenazine: A drug formerly used as an antipsychotic and treatment of various movement disorders. Tetrabenazine blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system.Rats, Sprague-Dawley: A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.Amine Oxidase (Copper-Containing): A group of enzymes including those oxidizing primary monoamines, diamines, and histamine. They are copper proteins, and, as their action depends on a carbonyl group, they are sensitive to inhibition by semicarbazide.KynuramineOxypurinol: A xanthine oxidase inhibitor.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Protein-Lysine 6-Oxidase: An enzyme oxidizing peptidyl-lysyl-peptide in the presence of water & molecular oxygen to yield peptidyl-allysyl-peptide plus ammonia & hydrogen peroxide. EC 1.4.3.13.Hydroxyindoleacetic AcidDepressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.Body Temperature: The measure of the level of heat of a human or animal.Homovanillic Acid3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.Enzyme Inhibitors: Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.Drug Synergism: The action of a drug in promoting or enhancing the effectiveness of another drug.Mitochondria, Liver: Mitochondria in hepatocytes. As in all mitochondria, there are an outer membrane and an inner membrane, together creating two separate mitochondrial compartments: the internal matrix space and a much narrower intermembrane space. In the liver mitochondrion, an estimated 67% of the total mitochondrial proteins is located in the matrix. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p343-4)Time Factors: Elements of limited time intervals, contributing to particular results or situations.Aldehyde Oxidase: An aldehyde oxidoreductase expressed predominantly in the LIVER; LUNGS; and KIDNEY. It catalyzes the oxidation of a variety of organic aldehydes and N-heterocyclic compounds to CARBOXYLIC ACIDS, and also oxidizes quinoline and pyridine derivatives. The enzyme utilizes molybdenum cofactor and FAD as cofactors.Glucose Oxidase: An enzyme of the oxidoreductase class that catalyzes the conversion of beta-D-glucose and oxygen to D-glucono-1,5-lactone and peroxide. It is a flavoprotein, highly specific for beta-D-glucose. The enzyme is produced by Penicillium notatum and other fungi and has antibacterial activity in the presence of glucose and oxygen. It is used to estimate glucose concentration in blood or urine samples through the formation of colored dyes by the hydrogen peroxide produced in the reaction. (From Enzyme Nomenclature, 1992) EC 1.1.3.4.Oxidation-Reduction: A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471).Biogenic Amines: A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology.Benzylamines: Toluenes in which one hydrogen of the methyl group is substituted by an amino group. Permitted are any substituents on the benzene ring or the amino group.Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.Oxidoreductases: The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9)Hydrogen Peroxide: A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials.Kinetics: The rate dynamics in chemical or physical systems.SemicarbazidesPhenylhydrazines: Diazo derivatives of aniline, used as a reagent for sugars, ketones, and aldehydes. (Dorland, 28th ed)Rabbits: The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.Oxidative Stress: A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi).Methoxyhydroxyphenylglycol: Synthesized from endogenous epinephrine and norepinephrine in vivo. It is found in brain, blood, CSF, and urine, where its concentrations are used to measure catecholamine turnover.NADH, NADPH Oxidoreductases: A group of oxidoreductases that act on NADH or NADPH. In general, enzymes using NADH or NADPH to reduce a substrate are classified according to the reverse reaction, in which NAD+ or NADP+ is formally regarded as an acceptor. This subclass includes only those enzymes in which some other redox carrier is the acceptor. (Enzyme Nomenclature, 1992, p100) EC 1.6.Norepinephrine Plasma Membrane Transport Proteins: Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of noradrenergic neurons. They remove NOREPINEPHRINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS. It regulates signal amplitude and duration at noradrenergic synapses and is the target of ADRENERGIC UPTAKE INHIBITORS.

Influence of vesicular storage and monoamine oxidase activity on [11C]phenylephrine kinetics: studies in isolated rat heart. (1/574)

[11C]Phenylephrine (PHEN) is a radiolabeled analogue of norepinephrine that is transported into cardiac sympathetic nerve varicosities by the neuronal norepinephrine transporter and taken up into storage vesicles localized within the nerve varicosities by the vesicular monoamine transporter. PHEN is structurally related to two previously developed sympathetic nerve markers: [11C]-meta-hydroxyephedrine and [11C]epinephrine. To better characterize the neuronal handling of PHEN, particularly its sensitivity to neuronal monoamine oxidase (MAO) activity, kinetic studies in an isolated working rat heart system were performed. METHODS: Radiotracer was administered to the isolated working heart as a 10-min constant infusion followed by a 110-min washout period. Two distinctly different approaches were used to assess the sensitivity of the kinetics of PHEN to MAO activity. In the first approach, oxidation of PHEN by MAO was inhibited at the enzymatic level with the MAO inhibitor pargyline. In the second approach, the two hydrogen atoms on the a-carbon of the side chain of PHEN were replaced with deuterium atoms ([11C](-)-alpha-alpha-dideutero-phenylephrine [D2-PHEN]) to inhibit MAO activity at the tracer level. The importance of vesicular uptake on the kinetics of PHEN and D2-PHEN was assessed by inhibiting vesicular monoamine transporter-mediated storage into vesicles with reserpine. RESULTS: Under control conditions, PHEN initially accumulated into the heart at a rate of 0.72+/-0.15 mL/min/g wet. Inhibition of MAO activity with either pargyline or di-deuterium substitution did not significantly alter this rate. However, MAO inhibition did significantly slow the clearance of radioactivity from the heart during the washout phase of the study. Blocking vesicular uptake with reserpine reduced the initial uptake rates of PHEN and D2-PHEN, as well as greatly accelerated the clearance of radioactivity from the heart during washout. CONCLUSION: These studies indicate that PHEN kinetics are sensitive to neuronal MAO activity. Under normal conditions, efficient vesicular storage of PHEN serves to protect the tracer from rapid metabolism by neuronal MAO. However, it is likely that leakage of PHEN from the storage vesicles and subsequent metabolism by MAO lead to an appreciable clearance of radioactivity from the heart.  (+info)

Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. (2/574)

The anticonvulsant activity of inhibitors of monoamine oxidase (MAO) was reported early after the development of irreversible MAO inhibitors such as tranylcypromine, but was never clinically used because of the adverse effects of these compounds. The more recently developed reversible MAO inhibitors with selectivity for either the MAO-A or MAO-B isoenzyme forms have not been studied extensively in animal models of epilepsy, so it is not known which type of MAO inhibitor is particularly effective in this respect. We compared the following drugs in the kindling model of epilepsy: 1) L-deprenyl (selegiline), i.e., an irreversible inhibitor of MAO-B, which, however, also inhibits MAO-A at higher doses, 2) the novel reversible MAO-B inhibitor LU 53439 (3,4-dimethyl-7-(2-isopropyl-1,3, 4-thiadiazol-5-yl)-methoxy-coumarin), which is much more selective for MAO-B than L-deprenyl, 3) the novel reversible and highly selective MAO-A inhibitor LU 43839 (esuprone; 7-hydroxy-3, 4-dimethylcoumarin ethanesulfonate), and 4) the irreversible nonselective MAO inhibitor tranylcypromine. Esuprone proved to be an effective anticonvulsant in the kindling model with a similar potency as L-deprenyl. In contrast to esuprone and L-deprenyl, the selective MAO-B inhibitor LU 53439 was not effective in the kindling model; this substantiates the previous notion that the anticonvulsant activity of L-deprenyl is not related to MAO-B inhibition, but to other effects of this drug, such as inhibition of MAO-A. Drugs inhibiting both MAO-A and MAO-B to a similar extent (tranylcypromine) or combinations of selective MAO-A and MAO-B inhibitors (esuprone plus LU 53439) had no advantage over MAO-A inhibition alone, but were less well tolerated. The data thus suggest that selective MAO-A inhibitors such as esuprone may be an interesting new approach for the treatment of epilepsy.  (+info)

Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. (3/574)

The reversible inhibitors of monoamine oxidase type A (RIMAs) are a newer group of antidepressants that have had much less impact on clinical psychopharmacology than another contemporary class of medications, the selective serotonin reuptake-inhibitors (SSRIs). The RIMAs agents are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility. As a result, dietary restrictions are not required during RIMA therapy, and hypertensive crises are quite rare. In this article, we describe a series of meta-analyses of studies of the two most widely researched RIMAs, moclobemide (MOC; Aurorex) and brofaromine (BRO). Our findings confirm that both BRO and MOC are as effective as the tricyclic antidepressants, and they are better tolerated. However, BRO is not being studied at present for reasons unrelated to efficacy or side effects. MOC, which is available throughout much of the world (but not the United States), is significantly more effective than placebo and, at the least, comparable to the SSRIs in both efficacy and tolerability. For MOC, higher dosages may enhance efficacy for more severe depressions. We also found evidence that supports clinical impressions that MOC is somewhat less effective, albeit better tolerated, than older MAOIs, such as phenelzine or tranylcypromine. Little evidence has yet emerged to suggest that the RIMAs share older MAOIs' utility for treatment of depressions characterized by prominent reverse neurovegetative features. Based on available evidence, the RIMAs appear to have a limited, but useful, role in the differential therapeutics of the depressive disorders.  (+info)

Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. (4/574)

1. Chronic treatment with low doses of the selective monoamine oxidase (MAO) type B inhibitors selegiline [(-)-deprenyl] and rasagiline, causes elevation in extracellular level of 3,4-dihydroxyphenylethylamine (dopamine) in the rat striatum in vivo (Lamensdorf et al., 1996). The present study was carried out to determine whether this effect of selegiline could be the result of an inhibition of the high-affinity dopamine neuronal transport process. 2. Changes in activity of the dopamine transporter (DAT) in vivo following selegiline treatment were evaluated indirectly by microdialysis technique in the rat, from the change in striatal dopamine extracellular concentration following systemic amphetamine administration (4 mg kg(-1), i.p.). Striatal levels of the DAT molecule were determined by immunoblotting. Uptake of [3H]-dopamine was determined in synaptosomes from selegiline-treated animals. 3. Amphetamine-induced increase in striatal extracellular dopamine level was attenuated by one day and by chronic (21 days) treatment with selegiline (0.25 mg kg(-1), s.c.). 4. Striatal levels of DAT were elevated after 1 and 21 days treatment with selegiline, but were not affected by clorgyline, rasagiline, nomifensine or amphetamine. 5. The increase in DAT expression, and attenuation of amphetamine-induced dopamine release, were not accompanied by a change in [3H]-dopamine uptake in synaptosomes of selegiline-treated animals. 6. The results suggest that a reversible inhibition of dopamine uptake occurs following chronic low dose selegiline treatment in vivo which may be mediated by an increase in endogenous MAO-B substrates such as 2-phenylethylamine, rather than by the inhibitor molecule or its metabolites. Increased DAT expression appears to be a special property of the selegiline molecule, since it occurs after one low dose of selegiline, and is not seen with other inhibitors of MAO-A or MAO-B. The new DAT molecules formed following selegiline treatment appear not to be functionally active.  (+info)

Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. (5/574)

BACKGROUND: Patients with atypical depression are more likely to respond to monoamine oxidase inhibitors than to tricyclic antidepressants. They are frequently offered psychotherapy in the absence of controlled tests. There are no prospective, randomized, controlled trials, to our knowledge, of psychotherapy for atypical depression or of cognitive therapy compared with a monoamine oxidase inhibitor. Since there is only 1 placebo-controlled trial of cognitive therapy, this trial fills a gap in the literature on psychotherapy for depression. METHODS: Outpatients with DSM-III-R major depressive disorder and atypical features (N = 108) were treated in a 10-week, double-blind, randomized, controlled trial comparing acute-phase cognitive therapy or clinical management plus either phenelzine sulfate or placebo. Atypical features were defined as reactive mood plus at least 2 additional symptoms: hypersomnia, hyperphagia, leaden paralysis, or lifetime sensitivity to rejection. RESULTS: With the use of an intention-to-treat strategy, the response rates (21-item Hamilton Rating Scale for Depression score, < or =9) were significantly greater after cognitive therapy (58%) and phenelzine (58%) than after pill placebo (28%). Phenelzine and cognitive therapy also reduced symptoms significantly more than placebo according to contrasts after a repeated-measures analysis of covariance and random regression with the use of the blind evaluator's final Hamilton Rating Scale for Depression score. The scores between cognitive therapy and phenelzine did not differ significantly. Supplemental analyses of other symptom severity measures confirm the finding. CONCLUSIONS: Cognitive therapy may offer an effective alternative to standard acute-phase treatment with a monoamine oxidase inhibitor for outpatients with major depressive disorder and atypical features.  (+info)

Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. (6/574)

To test the effect of selegiline, a specific monoamine oxidase B (MAO-B) inhibitor, on the cerebral metabolic and euphorigenic effects of cocaine in experienced users, eight cocaine-dependent (CD) subjects were evaluated using a within-subjects design. Each subject participated in two pairs of [F-18]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans (baseline scan followed 24 h later by a second scan obtained in conjunction with a 40-mg cocaine infusion) performed before and after a 1-week period of daily treatment with 10 mg selegiline administered orally. The hippocampus and amygdala were evaluated because of their hypothesized involvement in the addiction process, and the thalamus was evaluated as a comparison region. Following 7 days of selegiline treatment, the magnitude of the subjective euphoria ("high") produced by cocaine infusion was reduced by 40% (cocaine by selegiline interaction F = 7.15, df = 1.21, p = .014). Selegiline treatment also altered glucose utilization (normalized against whole brain counts) in the two limbic regions, but not the thalamus. In the amygdala, the effects of cocaine differed, depending upon whether or not patients were being treated with selegiline (cocaine by selegiline interaction F = 4.67, df = 1,19.8, p = .043). A different effect was observed in the hippocampus, where selegiline treatment decreased metabolic activity irrespective of whether cocaine was given (main effect F = 7.70, df = 1.20, p = .012). The concomitant changes in both the subjective experience of the "high" and normalized amygdala glucose utilization after selegiline treatment, suggest that a relationship exists between cocaine-induced euphoria and limbic metabolism. The data suggest that selegiline may be a useful adjunct in the treatment of cocaine dependence.  (+info)

Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. (7/574)

Broad-breasted white turkey poults fed furazolidone developed dilated cardiomyopathy (DCM) characterized by ventricular dilatation, decreased ejection fraction, beta1-receptor density, sarcoplasmic reticulum (SR) Ca2+-ATPase, myofibrillar ATPase activity, and reduced metabolism markers. We investigated the effects of carteolol, a beta-adrenergic blocking agent, by administrating two different dosages (0.01 and 10.0 mg/kg) twice a day for 4 wk to control and DCM turkey poults. At completion of the study there was 59% mortality in the nontreated DCM group, 55% mortality in the group treated with the low dose of carteolol, and 22% mortality in the group treated with the high dose of carteolol. Both treated groups showed a significant decrease in left ventricle size and significant restoration of ejection fraction and left ventricular peak systolic pressure. Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal. These results show that beta-blockade with carteolol improves survival, reverses contractile abnormalities, and induces cellular remodeling in this model of heart failure.  (+info)

Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. (8/574)

OBJECTIVE: To evaluate the efficacy and adverse effects of the type B monoamine oxidase inhibitor selegiline (also known as I-deprenyl) in the treatment of Alzheimer's disease. DESIGN: Long-term, double-blind, placebo-controlled trial. SETTING: Seven cities (1 or 2 nursing homes in each city) in the Czech and Slovak Republics. PATIENTS: A total of 173 nursing-home residents fulfilling the DSM-III criteria for mild to moderate Alzheimer's disease. INTERVENTIONS: Selegiline (10 mg per day) or placebo (both including 50 mg ascorbic acid) administered for 24 weeks. OUTCOME MEASURES: Clinical Global Impressions scale and Nurses Observation Scale for Inpatient Evaluation at baseline and at weeks 6, 12 and 24; Clock Drawing Test at baseline and 24 weeks, results of which were evaluated as normal or pathologic, and quantitatively on a modified 6-point scale; Sternberg's Memory Scanning test at baseline and at weeks 6, 12 and 24; Mini Mental State Examination, and electroencephalogram at baseline and 24 weeks; Structured Adverse Effects Rating Scale; physical, laboratory, hematological and electrocardiographic examinations at baseline and weeks 12 and 24. RESULTS: A total of 143 subjects completed enough of the trial to be entered in the analysis. Subjects were analyzed by 2 subgroups depending on whether they had a normal or pathologic result of the Clock Drawing Test. Analysis of variance showed significant improvement with selegiline versus placebo among those with a normal result of the Clock Drawing Test on the Mini Mental Status Examination (total score and orientation-place subscale) and among those with a pathologic result of the Clock Drawing Test of Sternberg's Memory Scanning test (for both speed and accuracy), on the Clinical Global Impressions scale as well as in terms of the dominant frequency on electroencephalograms. CONCLUSION: Selegiline has a long-term beneficial effect in Alzheimer's disease on memory modalities that reflect the function of the prefrontal areas of the brain, which are rich in dopamine receptors. The delayed appearance of differences between selegiline and placebo supports the notion that the mechanism of action is through neuronal rescue or neuroprotection. The differential response of patients with normal and pathologic results of the Clock Drawing Test may reflect the fact that the evaluation methods' sensitivity to change depends on the severity of dementia.  (+info)

Search Indian Monoamine Oxidase Inhibitor Manufacturers and Suppliers Details - Contact to Monoamine Oxidase Inhibitor Exporters in India, Monoamine Oxidase Inhibitor Wholesalers, Monoamine Oxidase Inhibitor Distributors and Traders from India.
In summary, we showed that brain and cerebellar cortex MAO-B availability affects 18F-THK5351 SUV. Following a single 10 mg oral dose of selegiline, 18F-THK5351 SUVs decreased by approximately 30 to 50% depending on the brain region, with the highest decline noted in the basal ganglia and thalamus which are known to express the highest concentrations of MAO-B in the brain [4]. The in vitro autoradiography blocking experiments showed similar effects. The long-lasting selegiline-evoked 18F-THK5351 SUV decline indicates MAO-B inhibition as the possible mechanism underlying this effect.. MAO-B is a protein highly expressed in all brain regions. It is compartmentalized in the outer membrane of the astrocytes mitochondria [18]. During the normal aging process, global MAO-B availability increases at the rate of nearly 9% per decade [19, 20]. In fact, MAO-B imaging has been proposed as a biomarker for astrocytosis in various neurodegenerative conditions associated with cell death or activation of immune ...
Focusing on new monoamine oxidase inhibitors: differently substituted coumarins as an interesting scaffold.: It is commonly accepted that monoamine oxidase (MAO
Monamine Oxidase Inhibitor is useful in treating patient with depression, atypical depression and social phobia. Monoamine oxidase inhibitor is given orally.
Generic Lexapro; Generic Luvox; Generic Pamelor; Generic Paxil; Generic Paxil Cr;. a monoamine oxidase inhibitor (MAOI); or; beta-blockers (Tenormin and others).Lexapro; Amoxil; Prednisone; Lasix; Allergies. Phenergan; Allegra; Flonase; Periactin; Deltasone; Astelin; Atarax.Lexapro And Low Heart Rate. thanks i really appreciate it. Similar Threads: Thread: Thread Starter:. Food and Drug take a monoamine oxidase inhibitor (MAOI).http://www.dentistmarket.com/store/refill.php?online=does-bystolic-have-maoi does bystolic have maoi Problèmes déchecs. http.How much does the job pay? buy detrol online Galapagos said it had received all rights to the GPR84 inhibitor. Im from England purchase lexapro online.. hap fiyatı şurup hangi durumlarda kullanılır. 2hci คือ information on the medication an 71 hydroxyzine is an maoi inhibitor. with lexapro much.. to 100 mg/m2, about should elapse between discontinuation Lexapro during. two protease inhibitor. pour linscription au permis bateau.. ...
Phenelzine is a monoamine oxidase inhibitor (MAOI) that works by increasing the levels of certain chemicals in the brain. Phenelzine is used to treat symptoms of depression that may include feelings of sadness, fear, anxiety, or worry about physical health (hypochondria). This medication is usually given after other...
Gen Hosp Psychiatry. 2012 Jan-Feb;34(1):102.e13-4. Epub 2011 Oct 2. Pardo JV. Source Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA. [email protected] Abstract This case report highlights the risk of nutritional supplements and misinformation obtained from the internet particularly for those on monamine oxdiase inhibitors (MAOIs). Despite sophisticated medical knowledge, this patient, who was taking…
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy. The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market. Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants. Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia. US Patent 4210655 Lotufo-Neto F, Trivedi M, Thase ME (1999). ...
What is Azilect (Rasagiline)? Rasagiline is a monoamine oxidase-B (MAO-B) inhibitor. It works by increasing the levels of certain chemicals in the brain. Rasagiline is used to treat the symptoms of Parkinsons disease. Rasagiline is sometimes used with another drug … Read more →. ...
The German biotechnology company said it will receive $10 million in upfront licensing fees as a result of Roches decision to collaborate on the development of the new compound, a monoamine oxidase type B inhibitor codenamed EVT-302. The agreement could also see Evotec receive development and milestone payments up to $820m and tiered double-digit royalties on sales should the drug candidate reach the market. Proof-of-concept clinical trials are scheduled to start next year ...
TB5 | MAO-B inhibitor | TB-5 | CAS [948841-07-4] | Axon 2629 | Axon Ligand™ with >100% purity available from supplier Axon Medchem, prime source of life science reagents for your research
The monoamine oxidase inhibitor drug L-deprenyl (phenylisopropyl methyl propynyl amine) may be safely and conveniently used for the treatment of mental depression, Parkinsons or Alzheimers Disease in a formulation applied to the skin of the patient. In this way the danger of side reaction due to the consumption of foods containing tyramine (the cheese effect) is minimized. Unlike other monoamine oxidase drugs, L-deprenyl does not cause skin irritation when used in this way.
Generic Name: Phenelzine (FEN-el-zeen) Drug Class: Antidepressant, MAO inhibitor Table of Contents Overview How to Take It Side Effects Warnings & Precautions Drug Interactions Dosage & Missing a Dose Storage Pregnancy or Nursing More Information Overview Nardil (phenelzine) is a monoamine oxidase inhibitor (MAOI) used
The FDA is alerting physicians and patients that the monoamine oxidase inhibitors, or MAOIs, linezolid and methylene blue have been linked to reports of serious central nervous system reactions in patients taking serotonergic psychiatric medications.
The NEW MAOI diet and drugs restrictions was posted June 11, 2013. This 4-page pamphlet is an important resource for patients taking MAO inhibitors as well as for health care providers (physicians, pharmacists, and dieticians).. Currently, an individual copy for an individual person can be printed and used for free.. ...
Zoloft is not a monoamine oxidase inhibitors, or MAOI, according to WebMD. Zoloft belongs to a class of antidepressants called selective serotonin reuptake inhibitors, or SSRIs, which work by...
Tricyclic antidepressants (TCAs), among the first antidepressants available, work to inhibit the reuptake of norepinephrine alone or the reuptake of both serotonin and norepinephrine.8 These medications have a narrow therapeutic efficacy and have been associated with cardiac toxicity. Doses 3 to 5 times greater than therapeutic doses have caused toxic levels, leading to prolongation of the QT interval and eventual arrhythmias. Side effects include anticholinergic and orthostatic effects, along with sedation, weight gain, and sexual dysfunction. Additionally, many TCAs exhibit interactions with other medications. As a result, they are used less frequently now as antidepressant therapy.2 Another older and less often prescribed class is the monoamine oxidase inhibitors (MAOIs). They irreversibly block monoamine oxidase, resulting in increased levels of serotonin, norepinephrine, and dopamine. The blockade of MAO in the gastrointestinal tract, however, results in an inability to metabolize tyramine, ...
|h1|AZILECT (RASAGILINE MESYLATE)|/h1| |h2|Azilect Description|/h2| |p|Azilect is an MAO-B inhibitor medication that is prescribed as an add-on drug to treat Parkinson’s disease (PD). It is believed that a decline in dopamine levels in your brain
Nardil tablets contain the active ingredient phenelzine, which is a type of antidepressant known as a monoamine oxidase inihibitor (MAOI).
Patients who have used the following prior to entry into Acute Phase: antipsychotics within 3 months, antidepressants including Monoamine oxidase inhibitors (MAOIs) within 1 month, anxiolytics within 2 weeks, mood-stabilizer (lithium, anticonvulsants) within 1 month, and/or high dose or prolonged benzodiazepine (continuous use for 3 months prior to admission) use ...
In some cases, monoamine oxidase inhibitors (MAOIs) are prescribed for anxiety treatment. However, as this eMedTV page explains, it doesnt happen very often. This selection explains why and also includes details on using benzodiazepines for anxiety.
Pivhydrazine (BAN), also known as pivalylbenzhydrazine and pivazide, is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family. It was formerly used as an antidepressant in the 1960s, but has since been discontinued.
Selegiline is an antidepressant (monoamine oxidase inhibitor) that treats depression by restoring the stability of certain natural substances (neurotransmitters) in the brain - low cost emsam zelapar online tab saturday delivery australia - emsam dementia in internet discount fedex - dementia symptomatic relief emsam 5mg online safe dhaka buy columbus. Buy emsam online
Natural monoamine oxidase enzyme inhibitors in fruits and vegetables may help explain the improvement in mood associated with switching to a plant-based diet.
McCabe-Sellers, B., Staggs, C., & Bogle, M. (2006). Tyramine in foods and monoamine oxidase inhibitor drugs: A crossroad where medicine, nutrition, pharmacy, and food industry converge. Journal Of Food Composition And Analysis, 19, S58-S65. http://dx.doi.org/10.1016/j.jfca.2005.12. ...
Storage conditions: Store at room temperature. Exposure to heat, light or air can affect flavor or aroma. Therefore keep out of direct light or heat. Keep sealed when not in use. Light to moderate clumping may occur. For healthy adults 18 years of age or older only. Consult with physician, if using prescription or over the counter medications, or have pre-existing conditions like: high/low blood pressure, cardiac arrhythmia, stroke, heart, liver, kidney or thyroid disease, seizure disorder, psychiatric disease, diabetes, prostate enlargement/urination issues; or if taking a Monoamine Oxidase inhibitor or erectile dysfunction medication. Discontinue use two weeks prior to surgery. In case of adverse reactions, discontinue immediately and consult health professional. Contains caffeine. Do not use: with caffeine/stimulants; alcohol, nitrates, under extreme conditions of heat, sleep deprivation or dehydration. Do not exceed recommended serving or use if safety seal is broken. Keep out of reach of ...
If you have a history of heat disease, or arteriosclerosis, glaucoma, if you have been on a monoamine oxidase inhibitor, or a history of drug or alcohol abuse, this is one drug you can forget. Also not to forget, if you have been prescribed Didrex by ...
Do not take Delsym if you have taken a monoamine oxidase inhibitor within the past two weeks. This eMedTV page describes several other important precautions and warnings to be aware of before taking Delsym, including when to call a doctor.
Phenelzine may interact with many different medicines, including other antidepressants and medications to help decrease blood pressure. A major concer
TCP has been shown to inhibit ,50% of human brain MAO-A after a three-day treatment with 10 mg/day (10). Clinical experience indicates that a small proportion of patients will get effects from that dose (I do not mean optimal or maximal effects, just noticeable ones), even sometimes significant postural hypotension - of the degree depicted in the bar graph in the MAOI_BP pdf. Illustrating BP changes at days 4 and 11.. It is generally supposed that approximately 85% inhibition is required for full clinical effect to occur.. Using the sound pharmacological principle of start low, go slow it is clearly prudent to start with no more than 20 mg per day, to assess the effect for 5 days by monitoring sitting and standing BP to ensure there is not an excessive postural drop at that dose - but note, near-maximum BP drop, on a constant dose, will take 10 days, or more, to develop. This is explained in the downloadable MAOI_BP pdf document the downloadable MAOI_BP pdf document here. NB I say sitting and ...
Take this medicine by mouth with a glass of water. Follow the directions on the prescription label. Take your medicine at regular intervals. Do not take your medicine more often than directed. Do not stop taking this medicine suddenly except upon the advice of your doctor. Stopping this medicine too quickly may cause serious side effects or your condition may worsen ...
NARDIL medication page for healthcare professionals to search for scientific information on Pfizer medications. Also find the prescibing information, announcements, resources, and channels to connect with Pfizer Medical Information.
Over the last 25 years the reputation of Mao Zedong has been seriously undermined by ever more extreme estimates of the numbers of deaths he was supposedly…
Monoamine oxidase B, also known as MAOB, is an enzyme that in humans is encoded by the MAOB gene. The protein encoded by this gene belongs to the flavin monoamine oxidase family. It is an enzyme located in the outer mitochondrial membrane. It catalyzes the oxidative deamination of biogenic and xenobiotic amines and plays an important role in the catabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. This protein preferentially degrades benzylamine and phenylethylamine. Like MAOA, it also degrades dopamine. Monoamine oxidase B has a hydrophobic bipartite elongated cavity that (for the "open" conformation) occupies a combined volume close to 700 Å3. hMAO-A has a single cavity that exhibits a rounder shape and is larger in volume than the "substrate cavity" of hMAO-B. The first cavity of hMAO-B has been termed the entrance cavity (290 Å3), the second substrate cavity or active site cavity (~390 Å3) - between both an isoleucine199 side-chain serves ...
TY - JOUR. T1 - Monoamine oxidase type a in fibroblasts from patients with bipolar depressive illness. AU - Breakefield, Xandra O.. AU - Giller, Earl L.. AU - Nurnberger, John I.. AU - Castiglione, Carmela M.. AU - Buchsbaum, Monte S.. AU - Gershon, Elliot S.. PY - 1980/7. Y1 - 1980/7. N2 - No differences in levels of type A monoamine oxidase (MAO) were observed in cultured human skin fibroblasts from nine patients with bipolar depressive illness as compared to 18 age-, sex-, and race-matched controls. All cells were biopsied and cultured under parallel conditions. Fibroblasts from monozygotic twins (three sets) had levels of MAO activity that were highly concordant, indicating that levels measured in fibroblasts are genetically determined. Together these findings suggest that an inherited predisposition to bipolar depressive illness does not involve inherited variations in levels of type A MAO activity. Using a larger control population, a positive correlation was observed between age of donor ...
Reference: Samsonova M.L., Oksenkrug G.F., Inhibition by monoamine oxidase inhibitors of substrate induction of liver tryptophan pyrrolase and increase in brain serotonin, Voprosy meditsinskoi khimii, 1972, vol: 18(2), 198-202 ...
The effects of d-amphetamine on food and water intake and brain monoamine concentrations in rats that had been deprived of food and water for 24 h were compared with those of two MAO inhibitors:...
2BK5: Demonstration of Isoleucine 199 as a Structural Determinant for the Selective Inhibition of Human Monoamine Oxidase B by Specific Reversible Inhibitors.
2C72: Functional Role of the Aromatic Cage in Human Monoamine Oxidase B: Structures and Catalytic Properties of Tyr435 Mutant Proteins
Westwood N.N. and Bryan-Lluka L.J. (1993) Types A and B monoamine oxidase contribute to the metabolism of norepinephrine in perfused lungs of rats. Journal of Pharmacology and Experimental Therapeutics, 267 2: 815-821. ...
The effect of L-deprenyl (selegiline) on the excitatory synaptic transmission was characterized in the CA1 neurons of rat hippocampal slices by using a intracellular recording technique. Superfusion of L-deprenyl (0.1-10 microM) reversibly decreased the EPSP, which was evoked by orthodromic stimulation of the Schaffer collateral-commissural afferent pathway in a concentration-dependent manner. The sensitivity of postsynaptic neurons to the glutamate receptor agonists, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid or N-methyl-D-aspartate, was not affected by L-deprenyl (1 microM) pretreatment. In addition, L-deprenyl (1 microM) clearly increased the magnitude of paired-pulse facilitation regardless of the interstimulus intervals of 20 to 300 msec used. The ability of L-deprenyl to decrease the EPSP amplitude was not observed in the dopamine-depleted rats. Pargyline and 4-phenylpyridine, the monoamine oxidase type B inhibitors, mimicked the depressant effect of L-deprenyl on the EPSP. ...
Looking for Monoamine Oxidase? Find out information about Monoamine Oxidase. Either of two enzymes found in the outer membrane of mitochondria that degrade biogenic amines and are thus responsible for the destruction of transmitter... Explanation of Monoamine Oxidase
As mentioned above, tranylcypromine acts as a nonselective and irreversible monoamine oxidase inhibitor. Regarding the isoforms of monoamine oxidase, it shows slight preference for the MAOB isoenzyme over MAO-A. In addition, tranylcypromine functions as a norepinephrine and dopamine releasing agent (NDRA) with approximately 1/10th the potency of amphetamine.. As a result of these actions, tranylcypromine considerably boosts the concentrations and activity of the monoamine neurotransmitters serotonin and dopamine, along with paradoxical and varying effects on norepinephrine and epinephrine. It increases the levels of the trace amines phenethylamine, tyramine, octopamine, and tryptamine as well. It is believed to be tranylcypromines action on these neurochemicals that is responsible for its therapeutic efficacy.. Tranylcypromine has also been shown to inhibit the histone demethylase, BHC110/LSD1. Tranylcypromine inhibits this enzyme with an IC50 , 2 µM, thus acting as a small molecule inhibitor ...
Creative Proteomics offer Monoamine Oxidase Activity (Total MAO/MAO-A/MAO-B) Fluorometric Assay Kit. We are specialized in manufacturing Assay Kits.
Azilect is a monoamine oxidase-B (MAO-B) inhibitor. It works by increasing the levels of certain chemicals in the brain. Azilect is used to treat the symptoms of Parkinsons disease (stiffness, tremors, spasms, poor muscle control). Azilect is sometimes used with another drug called levodopa. . Generic Azilect (Rasagiline 0.5/1mg) $ 1.00 pill - Alzheimers And Parkinsons @ MyMedsBuy.com - Official Drug Store Online. buy viagra online
Azilect is a monoamine oxidase-B (MAO-B) inhibitor. It works by increasing the levels of certain chemicals in the brain. Azilect is used to treat the symptoms of Parkinsons disease (stiffness, tremors, spasms, poor muscle control). Azilect is sometimes used with another drug called levodopa. . Generic Azilect (Rasagiline 0.5/1mg) C$ 1.32 pill - Alzheimers And Parkinsons @ MyMedsBuy.com - Official Drug Store Online. buy viagra online
Iproclozide is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued. It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
AIMS: To characterize potential mechanism-based inactivation (MBI) of major human drug-metabolizing cytochromes P450 (CYP) by monoamine oxidase (MAO) inhibitors, including the antitubercular drug isoniazid. METHODS: Human liver microsomal CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A activities were investigated following co- and preincubation with MAO inhibitors. Inactivation kinetic constants (KI and kinact) were determined where a significant preincubation effect was observed. Spectral studies were conducted to elucidate the mechanisms of inactivation. RESULTS: Hydrazine MAO inhibitors generally exhibited greater inhibition of CYP following preincubation, whereas this was less frequent for the propargylamines, and tranylcypromine and moclobemide. Phenelzine and isoniazid inactivated all CYP but were most potent toward CYP3A and CYP2C19. Respective inactivation kinetic constants (KI and kinact) for isoniazid were 48.6 µm and 0.042 min1 and 79.3 µm and 0.039 min1. Clorgyline was a selective ...
The gag reflex, swallowing ability of robotic technology, techniques, and the vagina to the intracellular enzyme monoamine oxidase inhibitor (maoi), selective serotonin reuptake inhibitor n. A type of involuntary contractions of the pleasure pain principle or (awkwardly but closer buy mg canada proscar 5 to the. Since its t is prolonged or bleeding current medication associated with the scalpel to the interpretation between gps and a review of a phenotype. Bmj 1999;368:244 167. Who distinguished it from the peritoneum during an eight-week spring training program in an article on the, depending on the stage of the canadian psychologist endel tulving. 412 disorders questions that search for and against the risks associated with psychotic disorders. [from greek dys- bad or abnormal + genein to produce, alluding to its classic mineralocorticoid properties, excess aldosterone causes coronary and the germanic languages such as d and its innervation to the ureter is typically not helpful for exposure. ...
... reversible inhibitor of monoamine oxidase A (RIMA),[9] a type of monoamine oxidase inhibitor (MAOI), and increases levels of ... "Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors ... A single 300 mg dose of moclobemide inhibits 80% of monoamine oxidase A (MAO-A) and 30% of monoamine oxidase B (MAO-B), ... Moclobemide (sold as Amira, Aurorix,[7] Clobemix , Depnil and Manerix[8]) is a reversible inhibitor of monoamine oxidase A ( ...
Monoamine oxidase inhibitors. Non-selective. *Irreversible: Benmoxin‡. *Iproclozide‡. *Iproniazid‡. *Isocarboxazid. *Isoniazid# ... See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine ... is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class developed and marketed by Wyeth (now part ... and is categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI). When most normal metabolizers take venlafaxine, ...
Monoamine oxidase inhibitors. Non-selective. *Irreversible: Benmoxin‡. *Iproclozide‡. *Iproniazid‡. *Isocarboxazid. *Isoniazid# ... Serotonin antagonists and reuptake inhibitors (e.g., etoperidone, hydroxynefazodone, lubazodone, mepiprazole, nefazodone, ...
Monoamine oxidase inhibitors. Non-selective. *Irreversible: Benmoxin‡. *Iproclozide‡. *Iproniazid‡. *Isocarboxazid. *Isoniazid# ... See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine ... Serotonin antagonists and reuptake inhibitors (e.g., etoperidone, hydroxynefazodone, lubazodone, mepiprazole, nefazodone, ... "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur. J. Pharmacol. 340 (2-3 ...
Treatment with monoamine oxidase inhibitors (MAOIs) 14 days or less prior to treatment with tianeptine. Due to the potential ... the selective serotonin reuptake inhibitors, the serotonin-norepinephrine reuptake inhibitors, moclobemide and numerous others ... Amineptine, the most closely related drug to have been widely studied, is a dopamine reuptake inhibitor with no significant ... coadministration of tianeptine and the selective serotonin reuptake inhibitor fluoxetine inhibited the effect of tianeptine on ...
Serotonin-norepinephrine-dopamine reuptake inhibitors. *Nefazodone. Monoamine oxidase inhibitors. *Phenelzine. *Tranylcypromine ... Serotonin antagonists and reuptake inhibitors (e.g., etoperidone, hydroxynefazodone, lubazodone, mepiprazole, nefazodone, ...
... effectively making it a broad-spectrum monoamine transporter inhibitor or "triple reuptake inhibitor."[11] ... See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine ... Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as ... inhibitor, it also has effects at the dopamine transporter (DAT), ...
Monoamine oxidase inhibitors. Non-selective. *Irreversible: Benmoxin‡. *Iproclozide‡. *Iproniazid‡. *Isocarboxazid. *Isoniazid# ... See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine ... SB-649,915 is a serotonin reuptake inhibitor and 5-HT1A and 5-HT1B receptor antagonist which is being investigated for its ... Serotonin antagonists and reuptake inhibitors (e.g., etoperidone, hydroxynefazodone, lubazodone, mepiprazole, nefazodone, ...
Monoamine oxidase inhibitors. Non-selective. *Irreversible: Benmoxin‡. *Iproclozide‡. *Iproniazid‡. *Isocarboxazid. *Isoniazid# ... See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine ... Nomifensine (Merital, Alival) is a norepinephrine-dopamine reuptake inhibitor, i.e. a drug that increases the amount of ... 2012). "4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors". Bioorg. Med. Chem. Lett. 22 ...
Monoamine oxidase inhibitors. Non-selective. *Irreversible: Benmoxin‡. *Iproclozide‡. *Iproniazid‡. *Isocarboxazid. *Isoniazid# ... See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine ... Reboxetine, sold under the brand name Edronax among others, is a drug of the norepinephrine reuptake inhibitor (NRI) class, ... Matthews PR, Horder J, Pearce M (January 2018). "Selective noradrenaline reuptake inhibitors for schizophrenia". The Cochrane ...
Monoamine oxidase inhibitors. Non-selective. *Irreversible: Benmoxin‡. *Iproclozide‡. *Iproniazid‡. *Isocarboxazid. *Isoniazid# ... See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine ... Pipofezine has been shown to act as a potent inhibitor of the reuptake of serotonin.[7][8] In addition to its antidepressant ... Serotonin antagonists and reuptake inhibitors (e.g., etoperidone, hydroxynefazodone, lubazodone, mepiprazole, nefazodone, ...
Monoamine oxidase inhibitors. Non-selective. *Irreversible: Benmoxin‡. *Iproclozide‡. *Iproniazid‡. *Isocarboxazid. *Isoniazid# ... See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine ... Paroxetine has been shown to be an inhibitor of G protein-coupled receptor kinase 2 (GRK2).[78][79] ... 354: Treatment with selective serotonin reuptake inhibitors during pregnancy". Obstetrics and Gynecology. 108 (6): 1601-3. doi: ...
Monoamine oxidase inhibitors. Non-selective. *Irreversible: Benmoxin‡. *Iproclozide‡. *Iproniazid‡. *Isocarboxazid. *Isoniazid# ... See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine ... LR-5182 is a stimulant drug which acts as a norepinephrine-dopamine reuptake inhibitor, structurally related to the better ... While LR-5182 itself never proceeded beyond initial animal studies, discovery of monoamine reuptake inhibition activity and ...
Krishnan KR (2007). "Revisiting monoamine oxidase inhibitors". The Journal of Clinical Psychiatry. 68 Suppl 8: 35-41. PMID ... another monoamine, in depression.[72][73] Lastly, increased activity of monoamine oxidase, which degrades monoamines, has been ... Irreversible monoamine oxidase inhibitors, an older class of antidepressants, have been plagued by potentially life-threatening ... The safety profile is different with reversible monoamine oxidase inhibitors, such as moclobemide, where the risk of serious ...
"Monoamine oxidase inhibitors (MAOIs)". Mayo Clinic. Retrieved 2017-08-08.. *^ "Tricyclic antidepressants (TCAs)". Mayo Clinic. ... through research on treating tuberculosis and yielded the class of antidepressants known as monoamine oxidase inhibitors (MAO ... Only two MAO inhibitors remain on the market in the United States because they alter the metabolism of the dietary amino acid ... SSRIs or selective serotonin reuptake inhibitors are the most frequently used antidepressant. These drugs share many ...
Monoamine oxidase inhibitors allow reuptake of biogenic amine neurotransmitters from the synapse, but inhibit an enzyme which ... "Irreversible Monoamine Oxidase Inhibitors Revisited". Psychiatric Times. Retrieved 7 November 2016.. *^ a b Wimbiscus, Molly; ... and deprenyl inhibits monoamine oxidase (MAO)-B and thus increases dopamine levels. ... Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are widely used antidepressants that specifically block the ...
Hydrazine (antidepressant) Monoamine oxidase inhibitor Tranylcypromine Isocarboxazid Parke-Davis Division of Pfizer Inc. (2007 ... Quitkin, F. M.; Mcgrath, P.; Liebowitz, M. R.; Stewart, J.; Howard, A. (1981). "Monoamine oxidase inhibitors in bipolar ... Phenelzine (Nardil, Nardelzine) is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class ... "The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice". Journal of Psychiatric Practice. 10 (4): 239-248. ...
Another type of antidepressant is a monoamine oxidase inhibitor, which is thought to block the action of Monoamine oxidase, an ... "Monoamine Oxidase Inhibitors". Stephen M. Stahl, M.D.; et al. (2004). "A Review of the Neuropharmacology of Bupropion, a Dual ... A commonly used class of antidepressants are called selective serotonin reuptake inhibitors (SSRIs), which act on serotonin ... Common stimulants: Methylphenidate (Ritalin, Concerta), a norepinephrine-dopamine reuptake inhibitor Dexmethylphenidate ( ...
Krishnan KR (2007). «Revisiting monoamine oxidase inhibitors». Journal of Clinical Psychiatry. 68 Suppl 8: 35-41. PMID 17640156 ... Delgado PL (2000). «Depression: The case for a monoamine deficiency». Journal of Clinical Psychiatry. 61 Suppl 6: 7-11. PMID ... Hirschfeld RM (2000). «History and evolution of the monoamine hypothesis of depression». Journal of Clinical Psychiatry. 61 ... Gunnell D, Saperia J, Ashby D (2005). «Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of ...
"Monoamine oxidase inhibitors (MAOIs)". Mayo Clinic. June 21, 2013. Targum, Steven D. (2014). "Identification and Treatment of ... monoamine oxidase inhibitors, or MAOIs, have also incurred a "poop-out" effect among depressed patients. Patients affected by ... "Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B". Biochemistry and Biophysics. 464 (2 ... "Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study ...
Monoamine oxidase B Inhibitors. 2 (4, Supplement): S27-S31. doi:10.1016/j.baga.2012.06.003. Gillman, P. K. (2005). "Monoamine ... Chapter 4 in Monoamine Oxidases and their Inhibitors. Volume 100 of International Review of Neurobiology. Eds Moussa Youdim, ... September 2004). "Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials ... Deprenyl the First Selective Inhibitor of B-Type Monoamine Oxidase and The First Synthetic Catecholaminergic Activity Enhancer ...
Irreversible monoamine oxidase inhibitors, an older class of antidepressants, have been plagued by potentially life-threatening ... The safety profile is different with reversible monoamine oxidase inhibitors such as moclobemide where the risk of serious ... Krishnan KR (2007). "Revisiting monoamine oxidase inhibitors". Journal of Clinical Psychiatry. 68 Suppl 8: 35-41. PMID 17640156 ... November 2006). "Elevated monoamine oxidase a levels in the brain: An explanation for the monoamine imbalance of major ...
A different class of antidepressants, the monoamine oxidase inhibitors, have historically been plagued by questionable efficacy ... Krishnan KR (2007). "Revisiting monoamine oxidase inhibitors". Journal of Clinical Psychiatry. 68 Suppl 8: 35-41. PMID 17640156 ... Selective serotonin reuptake inhibitors (SSRIs), such as sertraline (Zoloft, Lustral), escitalopram (Lexapro, Cipralex), ... July 2007). "Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour ...
Eberson, L. E; Persson, K (1962). "Studies on Monoamine Oxidase Inhibitors. I. The Autoxidation of Beta- ... "Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors". Biochemical ... is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an ... Phenylisopropylhydrazine As a Model Reaction for Irreversible Monoamine Oxidase Inhibition". Journal of medicinal and ...
Monoamine oxidase inhibitors allow reuptake of biogenic amine neurotransmitters from the synapse, but inhibit an enzyme which ... Bender, KJ; Walker, SE (8 October 2012). "Irreversible Monoamine Oxidase Inhibitors Revisited". Psychiatric Times. Retrieved 7 ... and deprenyl inhibits monoamine oxidase (MAO)-B and thus increases dopamine levels. The serotonin created by the brain ... Selective serotonin reuptake inhibitors (SSRIs) such as Prozac (fluoxetine) are widely used antidepressants that specifically ...
... redox agents and monoamine oxidase inhibitors". Food and Chemical Toxicology. 49: 1773-1781.. ... is modified to include binding of the inhibitor to the free enzyme:. EI. +. S. ⇌. k. 3. k. −. 3. E. +. S. +. I. ⇌. k. −. 1. k. ... is the inhibitor concentration.. V. max. {\displaystyle V_{\max }}. remains the same because the presence of the inhibitor can ... To compute the concentration of competitive inhibitor [. I. ]. {\displaystyle {\ce {[I]}}}. that yields a fraction f. V. 0. {\ ...
EFFECTS OF MONOAMINE OXIDASE INHIBITORS ON ADRENAL MEDULLARY RESPONSES TO NICOTINE AND TETRAMETHYL-AMMONIUM. John Gatgounis and ... EFFECTS OF MONOAMINE OXIDASE INHIBITORS ON ADRENAL MEDULLARY RESPONSES TO NICOTINE AND TETRAMETHYL-AMMONIUM. John Gatgounis and ... EFFECTS OF MONOAMINE OXIDASE INHIBITORS ON ADRENAL MEDULLARY RESPONSES TO NICOTINE AND TETRAMETHYL-AMMONIUM. John Gatgounis and ... Prior administration of a selected dose of a non-monoamine oxidase inhibitor, isoniazid, and a vehicle did not interfere with ...
Isocarboxazid belongs to a group of drugs called monoamine oxidase (MAO) inhibitors. It works by increasing the levels of ... in some cheeses and other foods that may cause dangerously high blood pressure in people taking monoamine oxidase inhibitors ( ... other MAO inhibitors such as phenelzine (Nardil), procarbazine (Matulane), tranylcypromine (Parnate), and selegiline (Eldepryl ... and selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), and ...
... tranylcypromine acts as a nonselective and irreversible monoamine oxidase inhibitor. Regarding the isoforms of monoamine ... Action of various inhibitors for the bovine kidney enzyme. Catalytic mechanism - Mitochondrial Monoamine Oxidase. II. ACTION OF ... Categories: Drugboxes which contain changes to watched fields , Monoamine oxidase inhibitors , Phenethylamines , ... it is a nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO).[1] It is used as an antidepressant and ...
mirtazapine, monoamine oxidase inhibitors (including moclobemide), SSRIs, tricyclics, venlafaxine. Antiparkinson agents ... Tramadol is contraindicated in patients who are taking monoamine oxidase inhibitors or who have taken them within the last 14 ... selective serotonin re-uptake inhibitors and antipsychotics can lower the seizure threshold.1 Prescribers should bear in mind ...
Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor) 10. Melatonin Related Therapies and Procedures. 1. Tourniquets ...
Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment ... Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. Arch Gen Psychiatry 42:962-966. ... Recent studies using the highly selective noradrenergic reuptake inhibitor, atomoxetine, demonstrate the role played by the ... Recent studies showing the improvement of ADHD symptoms obtained with the highly selective noradrenergic reuptake inhibitor, ...
ISOCARBOXAZID (eye soe kar BOX azid) is an monoamine oxidase inhibitor (MAOI). It is used to treat depression. ...
What is selective serotonin reuptake inhibitor? Meaning of selective serotonin reuptake inhibitor as a legal term. What does ... Definition of selective serotonin reuptake inhibitor in the Legal Dictionary - by Free online English dictionary and ... monoamine oxidase inhibitors (MOAIs) and selective serotonin reuptake inhibitors (SSRIs).. WHEN TERROR STRIKES CLINICIANS OFFER ... inhibitor. (redirected from selective serotonin reuptake inhibitor). Also found in: Dictionary, Thesaurus, Medical, Acronyms, ...
... is a monoamine oxidase inhibitor (MAOI) that works by increasing the levels of certain chemicals in the brain. ... Isocarboxazid is a monoamine oxidase inhibitor (MAOI) that works by increasing the levels of certain chemicals in the brain. ... Do not use isocarboxazid if you have used another MAO inhibitor in the past 14 days. A dangerous drug interaction could occur. ... Do not use isocarboxazid if you have used another MAO inhibitor in the past 14 days. A dangerous drug interaction could occur. ...
Monoamine oxidase inhibitors = MAOIs). MAOIs may include synthetic drugs, such as Apresoline, Adepren, Inkazan, etc, or herbal ... This may occur with simultaneous intake of two drugs that affect serotonin, such as selective serotonin reuptake inhibitors ( ...
... serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors). Some of the reported cases were fatal ... serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors. ... Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors ( ... Avoid concomitant use of ProvayBlue® with selective serotonin reuptake inhibitors (SSRIs), ...
Monoamine oxidase inhibitors-MAOIs): Marplan, Nardil. -(Anti-migraine medications): Axert, Amerge, Imitrex, Tegretol, Depakene ... Selective serotonin reuptake inhibitors-SSRIs): Celexa, Prozac, Sarafem, Paxil, Zoloft. -(Serotonin and norepinephrine reuptake ... inhibitors-SNRIs): Trazadone, Cymbalta, Effexor. -(Antidepressants/Tobacco-Addition Meds): Wellbutrin, Zyban. -(Tricyclic ...
Selegiline also is a reversible inhibitor of monoamine oxidase,.. Anti-DepressantAnti-Anxiety Anti-Depressant. (Olanzapine) is ...
monoamine oxidase inhibitors are a very powerful class of antidepressants. they prevent the breakdown of serotonin, dopamine, ... What are monoamine oxidase inhibitors (MAOIs)?. ANSWER Monoamine oxidase inhibitors are a very powerful class of ...
... acts on a wide range of endogenous monoamine substrates including the neurotransmitters, noradrenaline (NA), dopamine (DA), 5- ... SUZUKI, O., KATSUMATA, Y. & OYA, M. (1982). Substrate specificity of type A and type B monoamine oxidase. In Monoamine Oxidase ... GLOVER, V., REVELEY, M.A. & SANDLER, M. (1980). A monoamine oxidase inhibitor in human urine. Biochem. Pharmac, 29, 467-470. ... NEFF, N.H., YANG, H.Y.T. & FUENTES, A. (1974). The use of selective monoamine oxidase inhibitor drugs to modify amine ...
Monoamine oxidase inhibitors (MAOIs). MAOIs were the first type of antidepressant developed. Learn about the benefits, side ... Monoamine oxidase inhibitors (MAOIs) were the first type of antidepressant developed. Theyre effective, but theyve generally ... Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: Strategies for management of ... A reassessment of the safety profile of monoamine oxidase inhibitors: Elucidating tired old tyramine myths. Journal of Neural ...
... , MAO inhibitor, Phenelzine, Nardil, Tranylcypromine, Parnate. ... Inhibits monoamine oxidase. *Monoamine Oxidase is enzyme that breaks down biogenic amines (e.g. Norepinephrine, Serotonin, ... Type B Monoamine Oxidase affects Central Nervous System. *Older MAO inhibitors are nonspecific and affect both Type A and B (e. ... Monoamine Oxidase Inhibitor. search Monoamine Oxidase Inhibitor, MAO inhibitor, Phenelzine, Nardil, Tranylcypromine, Parnate ...
... , MAO inhibitor, Phenelzine, Nardil, Tranylcypromine, Parnate. ... Monoamine Oxidase Inhibitor. Monoamine Oxidase Inhibitor Aka: Monoamine Oxidase Inhibitor, MAO inhibitor, Phenelzine, Nardil, ... Inhibits monoamine oxidase. *Monoamine Oxidase is enzyme that breaks down biogenic amines (e.g. Norepinephrine, Serotonin, ... monoamine oxidase inhibitor used to treat depression and phobic disorders. Concepts. Pharmacologic Substance (T121) , Organic ...
... that block enzymatic breakdown of certain monoamine neurotransmitters: used to treat severe depression. Abbreviation: MAOI See ... Monoamine oxidase inhibitor definition, any of various substances, as isocarboxazid and phenelzine, ... biochem an agent that inhibits the action of monoamine oxidase. Such inhibitors are used in the treatment of depression ... Any of a class of antidepressant and hypotensive drugs that block the action of monoamine oxidase in the brain, thereby ...
Purchase Monoamine Oxidases and their Inhibitors, Volume 100 - 1st Edition. Print Book & E-Book. ISBN 9780123864673, ... Monoamine Oxidases and their Inhibitors, Volume 100 1st Edition. 0 star rating Write a review ... In this volume, invited experts provide authoritative reviews on various aspects of Monoamine Oxidase and its Inhibitors. ... BEHAVIORAL OUTCOMES OF MONOAMINE OXIDASE DEFICIENCY: PRECLINICAL AND CLINICAL EVIDENCE. I. General Characteristics of Monoamine ...
This refers to the effects of consuming tyramine-rich foods, such as cheese while medicated with monoamine oxidase inhibitors, ... Because of its selective, reversible inhibition of monoamine oxidase (MAO-A) and short half-life, unpleasant "cheese effects" ... Amine oxidase [flavin-containing] A. enzyme. DB08550. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. Phenylethanolamine N- ... Amine oxidase [flavin-containing] B. enzyme. DB00614. Furazolidone. ...
They work by blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. ... inhibitors are used to relieve certain types of mental depression. ... MAO inhibitors (monoamine oxidase inhibitors) were the first antidepressant medications invented that are generally available ... Monoamine oxidase (MAO) inhibitors are used to relieve certain types of mental depression. They work by blocking the action of ...
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: ... Antibiotics such as Linezolid Other monoamine oxidase inhibitors. MAOIs act by inhibiting the activity of monoamine oxidase, ... monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They have a long history of use as medications prescribed for the ... Reversible inhibitors of monoamine oxidase A (RIMAs) are a subclass of MAOIs that selectively and reversibly inhibit the MAO-A ...
Reversible monoamine oxidase-A inhibitors in resistant major depression. Download Prime PubMed App to iPhone, iPad, or Android ... Antidepressive AgentsDepressive DisorderDrug ResistanceHumansMonoamine OxidaseMonoamine Oxidase InhibitorsPiperidines ... Reversible monoamine oxidase-A inhibitors in resistant major depression.. Clin Neuropharmacol. 1993; 16 Suppl 2:S69-76.CN ... Reversible Monoamine oxidase-A Inhibitors in Resistant Major Depression. Clin Neuropharmacol. 1993;16 Suppl 2:S69-76. PubMed ...
Hypertensive crisis and broad complex bradycardia after a single dose of monoamine oxidase inhibitor. BMJ 1989; 298 :964 ... Hypertensive crisis and broad complex bradycardia after a single dose of monoamine oxidase inhibitor.. BMJ 1989; 298 doi: https ... Hypertensive crisis and broad complex bradycardia after a single dose of monoamine oxidase inhibitor. ... Hypertensive crisis and broad complex bradycardia after a single dose of monoamine oxidase inhibitor. ...
  • Accepted 19 June 2009 Recent studies showing the improvement of ADHD symptoms obtained with the highly selective noradrenergic reuptake inhibitor, atomoxetine, demonstrate that the noradrenergic system plays the role of pathophysiology in this disorder. (docme.ru)
  • moreover, dietary modifications are not usually necessary when taking a reversible inhibitor of MAO-A (i.e., moclobemide) or low doses of selective MAO-B inhibitors (e.g., selegiline 6 mg/24 hours transdermal patch). (wikipedia.org)
  • This study compares the neuroprotective abilities of M30 (a new generation inhibitor of both MAO A and MAO B) with rasagiline (Azilect ® , another new MAO B inhibitor) and selegiline (Deprenyl ® , a traditional MAO B inhibitor) in the prevention of dexamethasone-induced brain cell death and MAO activity in human neuroblastoma cells, SH-SY5Y. (frontiersin.org)
  • Summarily, M30 has a generally greater impact on neuroprotection than the MAO B inhibitors, selegiline and rasagiline. (frontiersin.org)
  • MAO-B inhibitors, rasagiline and selegiline [(−)deprenyl], protect neurons in animal and cellular models of neurodegeneration. (deepdyve.com)
  • In this paper, the involvement of MAOs in the induction of neuroprotective genes by MAO inhibitors was investigated in human glioblastoma U118MG cells expressing mainly MAO-B. Selegiline significantly increased Mao-B, which was suppressed by Mao-A knockdown with short interfering (si)RNA, whereas rasagiline less markedly increased Mao-B, which was not affected by Mao-A knockdown. (deepdyve.com)
  • Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline. (aspetjournals.org)
  • The monoamine oxidase inhibitors R-(-)-deprenyl (deprenyl) and clorgyline inactivated the 7-ethoxy-4-trifluoromethylcoumarin O-deethylase activity of purified cytochrome P4502B1 (P4502B1) in a reconstituted system containing P4502B1, NADPH-cytochrome P450 oxidoreductase, and L-alpha-phosphatidylcholine dilauroyl as the lipid. (aspetjournals.org)
  • MAO was also found to be almost 500 times more sensitive to its selective inhibitor deprenyl than to chlorogilyn. (springer.com)
  • There are some contraindications to the use of MAO inhibitors , including severe liver and kidney impairment, severe or frequent headache, uncontrolled hypertension, cardiovascular diseases, and cerebrovascular diseases (Savinelli & Halpern 1995), but Brush et al. (thefreedictionary.com)
  • Evidence for an endogenous inhibitor of platelet MAO in chronic schizophrenia. (springer.com)
  • The endogenous inhibitor of monoamine oxidase A (MAO-AI) was measured in the same saliva samples in order to explore the relationship between circadian activation of the hypothalamic-pituitary-adrenocortical (HPA) axis and MAO-AI. (westminster.ac.uk)
  • These results demonstrate that spinal monoamine release is modulated on a timescale of seconds, in tandem with centrally-generated locomotion and indicate that MLR-evoked locomotor activity involves concurrent activation of descending monoaminergic and reticulospinal pathways. (frontiersin.org)
  • The compounds of the present invention were inactive against MAO-A. However, these simple pyridazinone derivatives are inhibitors MAO-B with IC50 values in the micromolar range. (innoget.com)
  • Because the analgesic potential of monoamine oxidase-A (MAO-A) inhibitors is understudied, we evaluated the potential antinociceptive effect of the reversible MAO-A inhibitors moclobemide and 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in a mouse neuropathic pain model induced by chronic constriction injury (CCI) of the sciatic nerve. (ovid.com)